BridgeBio Oncology details 2026 shareholder vote results
BridgeBio Oncology Therapeutics, Inc. reported results from its June 16, 2026 Annual Meeting of Stockholders and a board change.
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics, Inc. reported results from its June 16, 2026 Annual Meeting of Stockholders and a board change. Director Michelle Doig resigned from the Board at the end of her term as a Class I director, and the company stated her resignation was not due to any disagreement regarding operations, policies or practices.
Stockholders elected two Class I directors. Peter Lebowitz received 31,822,504 votes for and 3,372 withheld. Frank P. McCormick received 25,654,119 votes for and 6,171,757 withheld. The company reported 2,713,439 broker non-votes and 13,805,126 no votes on this proposal.
Stockholders also ratified the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,535,875 votes for, 3,440 against and no abstentions, and 13,805,126 no votes reported for this proposal.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 5.07
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares entitled to vote: 80,112,725 shares
Shares represented: 48,344,441 shares
Votes for Lebowitz: 31,822,504 votes
+5 more
8 metrics
Shares entitled to vote
80,112,725 shares
Common stock entitled to vote at 2026 Annual Meeting
Shares represented
48,344,441 shares
Common stock present or by proxy at 2026 Annual Meeting
Votes for Lebowitz
31,822,504 votes
Election of Peter Lebowitz as Class I director
Votes for McCormick
25,654,119 votes
Election of Frank P. McCormick as Class I director
Broker non-votes on directors
2,713,439 votes
Broker non-votes for director election proposal
Votes for auditor ratification
34,535,875 votes
Ratification of Deloitte & Touche LLP for 2026 fiscal year
Votes against auditor ratification
3,440 votes
Ratification of Deloitte & Touche LLP for 2026 fiscal year
No votes on auditor proposal
13,805,126 votes
No votes reported for auditor ratification proposal
Key Terms
Annual Meeting of Stockholders, Class I director, broker non-votes, independent registered public accounting firm, +1 more
5 terms
Annual Meeting of Stockholders financial
"The proposals set forth below were submitted to the stockholders at the Annual Meeting held on June 16, 2026"
Class I director financial
"her resignation as a member of the Board of Directors ... as a Class I director"
A class I director is a member of a company’s board who belongs to one of several groups whose terms expire in a specified year under a staggered election system; each class is elected on a different cycle so only a portion of the board faces re-election each year. This matters to investors because it affects how quickly control of the board can change, the company’s continuity and oversight, and the ease of mounting or defending against takeover efforts—think of a team where only some players are replaced each season rather than the whole roster at once.
broker non-votes financial
"There were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What board change did BridgeBio Oncology Therapeutics (BBOT) report in this 8-K?
BridgeBio Oncology Therapeutics reported that Michelle Doig resigned from its Board as a Class I director effective June 16, 2026. The company stated her resignation was not due to any disagreement about its operations, policies, or practices, indicating an orderly end-of-term transition rather than a dispute.
Which directors were elected at BridgeBio Oncology Therapeutics’ 2026 Annual Meeting?
Stockholders elected Peter Lebowitz and Frank P. McCormick as Class I directors to serve until the 2029 Annual Meeting. Lebowitz received 31,822,504 votes for and 3,372 withheld, while McCormick received 25,654,119 votes for and 6,171,757 withheld, plus reported broker non-votes and no votes.
Did BridgeBio Oncology Therapeutics stockholders ratify Deloitte & Touche as auditor for 2026?
Yes. Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 34,535,875 votes for, 3,440 against, no abstentions, and 13,805,126 reported as no votes on this ratification proposal.
AI-generated analysis. How Rhea-AI works. Not financial advice.
